Lancet 2018 Oct 18
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
Abstract
Background
Based on previous findings, we hypothesised that radiotherapy to the prostate would improve overall survival in men with metastatic prostate cancer, and that the benefit would be greatest in patients with a low metastatic burden. We aimed to compare standard of care for metastatic prostate cancer, with and without radiotherapy.
Methods
We did a randomised controlled phase 3 trial at 117 hospitals in Switzerland and the UK. Eligible patients had newly diagnosed metastatic prostate cancer. We randomly allocated patients open-label in a 1:1 ratio to standard of care (control group) or standard of care and radiotherapy (radiotherapy group). Randomisation was stratified by hospital, age at randomisation, nodal involvement, WHO performance status, planned androgen deprivation therapy, planned docetaxel use (from December, 2015), and regular aspirin or non-steroidal anti-inflammatory drug use. Standard of care was lifelong androgen deprivation therapy, with up-front docetaxel permitted from December, 2015. Men allocated radiotherapy received either a daily (55 Gy in 20 fractions over 4 weeks) or weekly (36 Gy in six fractions over 6 weeks) schedule that was nominated before randomisation. The primary outcome was overall survival, measured as the number of deaths; this analysis had 90% power with a one-sided α of 2·5% for a hazard ratio (HR) of 0·75. Secondary outcomes were failure-free survival, progression-free survival, metastatic progression-free survival, prostate cancer-specific survival, and symptomatic local event-free survival. Analyses used Cox proportional hazards and flexible parametric models, adjusted for stratification factors. The primary outcome analysis was by intention to treat. Two prespecified subgroup analyses tested the effects of prostate radiotherapy by baseline metastatic burden and radiotherapy schedule. This trial is registered with ClinicalTrials.gov, number NCT00268476.
Findings
Between Jan 22, 2013, and Sept 2, 2016, 2061 men underwent randomisation, 1029 were allocated the control and 1032 radiotherapy. Allocated groups were balanced, with a median age of 68 years (IQR 63-73) and median amount of prostate-specific antigen of 97 ng/mL (33-315). 367 (18%) patients received early docetaxel. 1082 (52%) participants nominated the daily radiotherapy schedule before randomisation and 979 (48%) the weekly schedule. 819 (40%) men had a low metastatic burden, 1120 (54%) had a high metastatic burden, and the metastatic burden was unknown for 122 (6%). Radiotherapy improved failure-free survival (HR 0·76, 95% CI 0·68-0·84; p<0·0001) but not overall survival (0·92, 0·80-1·06; p=0·266). Radiotherapy was well tolerated, with 48 (5%) adverse events (Radiation Therapy Oncology Group grade 3-4) reported during radiotherapy and 37 (4%) after radiotherapy. The proportion reporting at least one severe adverse event (Common Terminology Criteria for Adverse Events grade 3 or worse) was similar by treatment group in the safety population (398 [38%] with control and 380 [39%] with radiotherapy).
Interpretation
Radiotherapy to the prostate did not improve overall survival for unselected patients with newly diagnosed metastatic prostate cancer.
Funding
Cancer Research UK, UK Medical Research Council, Swiss Group for Clinical Cancer Research, Astellas, Clovis Oncology, Janssen, Novartis, Pfizer, and Sanofi-Aventis.
Related Questions
Does long term use of 5 alpha reductase inhibitors change the way you evaluate a PSMA PET?
I am not aware of any specific studies that answer this question, but you could consider this situation similar to a patient on ADT, where there is the possibility that treatment may reduce the sensitivity of imaging. (n.b., a prior post discusses the influence of ADT on PSMA-based PET/CT). In this ...
Would you consider treating a patient with prostate cancer and biopsy-proven involved inguinal nodes with radiation to the prostate/pelvis/groin?
Would favor starting with ADT plus ASRI and base subsequent treatment in 3 to 6 months based on responses ranging from prostate-only RT (like STAMPEDE for nonregional node) or definitive RT to primary and node.
What are your top takeaways in GU Cancers from ESMO 2024?
1. Tivozanib–nivolumab vs tivozanib monotherapy in patients with renal cell carcinoma (RCC) following 1 or 2 prior therapies including an immune checkpoint inhibitor (ICI): Results of the phase III TiNivo-2 study. This trial confirmed (along with CONTACT-03: cabozantinib +/- atezolizumab) that cont...
Do you ever dose escalate radiotherapy to the primary in low volume metastatic prostate cancer?
Background: STAMPEDE Arm H (SOC ± RT to prostate) allowed for two fractionation schedules, 55 Gy in 20 daily fractions (67 Gy EQD2[α/β = 1.5]) and 36 Gy in 6 weekly fractions (77 Gy EQD2[α/β = 1.5]), without correction for treatment duration), and approximately half of participants received each sch...
Do you offer RT both to the prostate and synchronous oligometastases in de novo oligometastatic prostate cancer?
We do not yet have good evidence to tell us whether or when we should offer metastasis-directed therapy (MDT) for de novo oligometastatic prostate cancer. ORIOLE (like STOMP) was conducted in the recurrent setting. Those trials showed that MDT could delay progression and possibly allow a delay in th...
Do you offer prostate RT to men with 0-3 bone metastases on conventional imaging when PSMA PET shows a very high number of M1 lesions?
This would be a hard no from my standpoint.I get the rationale here. STAMPEDE found a survival benefit for prostate-directed RT in men with "low volume" disease, which was defined based on the CHAARTED trial with conventional imaging. Therefore, men with low-volume disease on conventional imaging fi...
In what situations would a standard FDG PET/CT be useful in the evaluation of high risk prostate cancer?
Overall, my impression is that the use of FDG PET for this purpose is limited. If interested, below is my rationale as summarized in the Conclusion.As mentioned, PSMA PET/CT is considered by many to be the current best standard of care for the staging evaluation of high-risk prostate cancer, and it ...
Are there any patient characteristics that make you change fractionation when treating per STAMPEDE?
I generally favor 55/20 for patients where I am treating just the prostate in the setting of non-oligometastatic disease, and not treating the other metastases. It is a relatively low dose and I can't think of a scenario where I would turn the dose down for any patient factors. 6 Gy x 6 is very reas...
How would you work up a patient with prostate cancer with bone scan suspicious for metastatic disease and a negative PSMA PET/CT?
While some bone metastases are 99mTc-positive and PSMA-negative, this circumstance is quite rare (< 2%). Based on this alone, in cases like this, I typically conclude that the patient is clinically M0. However, I do consider 3 other factors: the prevalence of bone metastases within the patient’s par...
Is there evidence that radiotherapy to less than all sites of oligometastatic prostate cancer is beneficial?
The ORIOLE trial referenced above helps to answer this question. Within the SBRT arm (n=36), patients received PSMA PET, however, the treating rad oncs were blinded to the result and patients were "consolidated" based on conventional imaging. Treatment plans were then reviewed and compared to PSMA, ...
Would you treat a prostate cancer patient with a positive peri-aortic node?
Such patients are good candidates for treatment. Patients with non-regional LNs (M1a) were included on STAMPEDE. In the M1a subgroup analysis presented at ESMO 2019, there was a significant improvement in FFS (HR 0.64, 0.43-0.96) and a trend to improvement in OS (HR 0.62, 0.35-1.09) (~180 patients i...
What is your preferred choice and timing of systemic therapy in a patient with high risk oligometastatic prostate cancer undergoing metastasis directed therapy to all sites of disease, including the prostate?
Metastasis-directed therapy (MDT) is an option for patients with oligometastatic prostate cancer who wish to delay initiation of ADT, based on STOMP (Decaestecker et al., PMID: 25223986) and ORIOLE (Phillips et al., PMID: 32215577) trials. In the STOMP study, 61% of patients (3 or fewer metastases) ...
Would you consider applying the principles of STAMPEDE with <5 oligometastatic non-regional lymph nodes from prostate cancer?
About 25% in STAMPEDE had low volume metastatic disease with no bone Mets, with most having a non-regional node in that category to qualify as low volume Mets.That being said, common iliac could be the primary drainage of prostate cancer based on SNLN studies and I would favor treating like node-pos...
Is there a subset of patients with metastatic breast cancer in whom you would consider locoregional therapy?
E2108 is a negative trial for LRT for stage IV disease. We need to see the publication to see details. The issue is if this trial had enough power to detect a difference. The trial was designed to detect an improvement in 3 year OS rate from 30% with OST alone to 49.3% for OST+LRT. The final results...
For prostate cancer patients with N+ disease, is there evidence demonstrating improved outcomes with the addition of nodal RT, as opposed to prostate RT alone plus ADT?
There is no direct evidence. In the STAMPEDE trial, which showed benefit of RT in node positive patients, RT involved prostate and nodes in a majority of patients (>80%).
How would you manage a patient with intact prostate cancer with metastases to a para-aortic node and single bone?
I would consider treating the primary site per STAMPEDE as well as possible SABR the other lesions, so long as he understands this is an evolving area and the benefit has not been conclusively demonstrated. Would recommend confirming the bone lesion by biopsy as well.
Which patients with metastatic hormone sensitive prostate cancer would you treat with enzalutamide or apalutamide (instead of abiraterone or docetaxel)?
Current studies in mHSPC combining docetaxel or abiraterone or enzalutamide or apalutamide suggest that the standard of care for patients who present with de novo high volume metastatic disease has now changed from single ADT (gonadal androgen suppression) to one of the combinations. At this point i...
When treating a patient definitively for high risk prostate cancer, how would you interpret the interval development of sclerotic bone lesions that appeared during neoadjuvant ADT?
It most likely reflects treated metastatic disease but can be very difficult to prove, as bx yield is low since it has been treated. Would not change management and complete planned treatment. Stampede also showed benefit of local RT for limited bone mets
How would you manage prostate cancer with isolated presacral nodal metastasis?
Unfortunately, we can't really use RTOG 0521 to guide us here, as men with involved nodes detected by imaging were excluded. Also, according to the AJCC 8th edition staging manual, pre-sacral nodal involvement would be considered N1 rather than M1a, so although this man is at high risk for subsequen...
How would you approach a patient with Gleason 9 prostate cancer and regional lymphadenopathy as well as inguinal lymphadenopathy (M1a) but no bone metastases?
Definitely warrants a balanced discussion. Systemic therapy as the mainstay is definitely the right answer--long-term ADT for sure, at minimum. I think offering to treat the prostate with RT is fair, based on STAMPEDE. For a fit patient with good life expectancy, I would explain to the patient that ...